Published in Blood on October 24, 2002
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med (2008) 1.53
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res (2007) 1.41
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am (2013) 1.22
Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem (2009) 1.20
Plexin-A4-semaphorin 3A signaling is required for Toll-like receptor- and sepsis-induced cytokine storm. J Exp Med (2010) 1.12
Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica (2010) 1.11
Biology and function of neuroimmune semaphorins 4A and 4D. Immunol Res (2011) 1.03
Semaphorins and their receptors in lung cancer. Cancer Lett (2008) 1.02
Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev Immunol (2013) 1.00
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta (2015) 0.98
Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells. J Exp Clin Cancer Res (2009) 0.97
Semaphorins: a new class of immunoregulatory molecules. Philos Trans R Soc Lond B Biol Sci (2005) 0.96
Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma. PLoS Genet (2013) 0.94
Plexin-D1 is a novel regulator of germinal centers and humoral immune responses. J Immunol (2011) 0.94
Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood (2011) 0.91
Immune plexins and semaphorins: old proteins, new immune functions. Protein Cell (2013) 0.88
Plexin-B2 and Plexin-D1 in dendritic cells: expression and IL-12/IL-23p40 production. PLoS One (2012) 0.86
Protection against colitis by CD100-dependent modulation of intraepithelial γδ T lymphocyte function. Mucosal Immunol (2013) 0.84
Plexin-B2 negatively regulates macrophage motility, Rac, and Cdc42 activation. PLoS One (2011) 0.83
Semaphorin signals on the road to cancer invasion and metastasis. Cell Adh Migr (2007) 0.81
Roles of semaphorins in the immune and hematopoietic system. Rheumatol Int (2009) 0.80
Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells. J Immunol (2016) 0.80
Semaphorin-4D (Sema-4D), the Plexin-B1 ligand, is involved in mouse ovary follicular development. Reprod Biol Endocrinol (2007) 0.79
Neuroimmune semaphorin 4D is necessary for optimal lung allergic inflammation. Mol Immunol (2013) 0.77
Transmembrane semaphorins: Multimodal signaling cues in development and cancer. Cell Adh Migr (2016) 0.76
Chemokine-mediated B cell trafficking during early rabbit GALT development. J Immunol (2014) 0.76
A reverse signaling pathway downstream of Sema4A controls cell migration via Scrib. J Cell Biol (2016) 0.75
Impacts of K562 cells towards activities of Toll-like receptor pathway of human mesenchymal stem cell-bone marrow. Int J Clin Exp Med (2015) 0.75
Plexin-A1 is required for Toll-like receptor-mediated microglial activation in the development of lipopolysaccharide-induced encephalopathy. Int J Mol Med (2014) 0.75
Stage-specific functions of Semaphorin7A during adult hippocampal neurogenesis rely on distinct receptors. Nat Commun (2017) 0.75
Intact CD100-CD72 Interaction Necessary for TCR-Induced T Cell Proliferation. Front Immunol (2017) 0.75
Interferon-α-induced CD100 on naïve CD8(+) T cells enhances antiviral responses to hepatitis C infection through CD72 signal transduction. J Int Med Res (2017) 0.75
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med (2009) 4.27
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood (2009) 3.56
Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol (2005) 3.50
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature (2002) 2.99
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell (2005) 2.85
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood (2006) 2.77
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74
Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood (2004) 2.71
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood (2008) 2.71
Negative receptor signalling. Curr Opin Cell Biol (2003) 2.68
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 2.66
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood (2012) 2.14
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood (2011) 1.96
Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81
MicroRNAs impair MET-mediated invasive growth. Cancer Res (2008) 1.81
Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol (2002) 1.80
Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res (2010) 1.73
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
Targeting B-cell anergy in chronic lymphocytic leukemia. Blood (2013) 1.66
Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol (2008) 1.65
Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood (2005) 1.65
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology (2011) 1.61
Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood (2003) 1.61
Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol (2008) 1.60
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med (2008) 1.53
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res (2010) 1.51
Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood (2003) 1.50
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood (2011) 1.49
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A (2006) 1.47
Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood (2010) 1.44
The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood (2002) 1.44
Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene (2004) 1.43
Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther (2002) 1.41
Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep (2004) 1.39
Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood (2004) 1.39
Hepatocyte growth factor and its receptor are required for malaria infection. Nat Med (2003) 1.37
HGF/MET signalling protects Plasmodium-infected host cells from apoptosis. Cell Microbiol (2005) 1.28
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood (2005) 1.24
Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett (2013) 1.23
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood (2010) 1.22
Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res (2004) 1.21
Molecular cancer therapy: can our expectation be MET? Eur J Cancer (2008) 1.19
HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med (2011) 1.17
Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem (2004) 1.16
Antigen selection in B-cell lymphomas--tracing the evidence. Semin Cancer Biol (2013) 1.16
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood (2009) 1.15
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer (2010) 1.14
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood (2013) 1.14
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. Leuk Res (2007) 1.13
IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors. Eur J Immunol (2006) 1.13
Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol (2008) 1.12
The origin of B-cell chronic lymphocytic leukemia. Semin Oncol (2006) 1.11
A novel Rag2-/-gammac-/--xenograft model of human CLL. Blood (2009) 1.11
Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Cancer Res (2007) 1.10
Chronic lymphocytic leukemia. Crit Rev Oncol Hematol (2007) 1.10
Semaphorin 4D regulates gonadotropin hormone-releasing hormone-1 neuronal migration through PlexinB1-Met complex. J Cell Biol (2008) 1.09
Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. Blood (2008) 1.09
MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res (2006) 1.09